

References

I-40

1. American Society of Clinical Oncology (ASCO) issues two new guidelines on treating patients with advanced, HER2-positive breast cancer. *American Society of Clinical Oncology*. May 2014.
2. Wolff A, Hammond M, Hicks D, et al. American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update: Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. *Arch Pathol Lab Med*. 2014 Feb; 138(2): 241–256.
3. Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. *New England Journal of Medicine*. Feb 19 2015;372(8):724-734.
4. Park Y, Shin H, Jung H, et al. Role of HER2 mutations in refractory metastatic breast cancers: Targeted sequencing results in patients with refractory breast cancer. *Oncotarget* 2015.
5. Giordano S, Temin S, Kirshner J, et al. Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol* 2014.
6. Gianni L, Pienkowski T, Young-Hyuck I, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomized multicenter, open-label, phase 2 trial. *Lancet Oncol*. 2012;13 (1,) 25–32.
7. Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. *Lancet Oncol* 2016; 17: 791–800.
8. Perez, EA, Barrios C, Wiermann W, et al. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. *J Clin Oncol*. 2016;141-148.
9. MICROMEDEX®SOLUTIONS Compendia. 2017. Pertuzumab.
10. Clinical Pharmacology Compendia. 2018. Tampa FL: Gold Standard, Inc. Pertuzumab.
11. PERJETA® (pertuzumab) [package insert]. South San Francisco, CA: Genentech, Inc.; 2017.
12. NCCN Drugs & Biologics Compendium™. Breast Cancer. 2017. National Comprehensive Cancer Network (NCCN).
13. Dang C, Iyengar N, Datko F, et al. Phase II Study of Paclitaxel Given Once per Week Along With Trastuzumab and Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer. *J Clin Oncol*. 2015; 33:442-447.
14. Tiwari S, Mishara P, Raska P, et al. Retrospective Study of the Efficacy and Safety of Neoadjuvant Docetaxel, Carboplatin, Trastuzumab/Pertuzumab (TCH-P) in Nonmetastatic HER2-Positive Breast Cancer. *Breast Cancer Res Treat*. 2016;158:189-193.

15. Urruticoechea A, Rizwanullah M, Im S, et al. Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy. *J Clin Oncol*. 2017;35:3030-3038.